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The combined use of the histone deacetylase inhibitor valproic acid (VPA), the retinoic acid receptor-𝛼 agonist all-trans retinoic
acid (ATRA), and the deoxyribonucleic acid polymerase-𝛼 inhibitor cytarabine (Ara-C) is now considered for disease-stabilizing
treatment of acute myeloid leukemia (AML). Leukemogenesis and leukemia cell chemoresistance seem to be supported by
neighbouring stromal cells in the bone marrow, and we have therefore investigated the effects of these drugs on primary human
endothelial cells and the osteoblastic Cal72 cell line. The results show that VPA and Ara-C have antiproliferative effects, and the
antiproliferative/cytotoxic effect of Ara-C was seen at low concentrations corresponding to serum levels found during low-dose
in vivo treatment. Furthermore, in functional assays of endothelial migration and tube formation VPA elicited an antiangiogenic
effect, whereas ATRA elicited a proangiogenic effect. Finally, VPA and ATRA altered the endothelial cell release of angiogenic
mediators; ATRA increased levels of CXCL8, PDGF-AA, and VEGF-D, while VPA decreased VEGF-D and PDGF-AA/BB levels
and both drugs reducedMMP-2 levels. Several of these mediators can enhance AML cell proliferation and/or are involved in AML-
induced bonemarrow angiogenesis, and direct pharmacological effects on stromal cellsmay thus indirectly contribute to the overall
antileukemic activity of this triple drug combination.
1. Introduction
Acute myeloid leukemia (AML) is an aggressive bone mar-
row malignancy and several studies have demonstrated
that different types of bone marrow stromal cells support
leukemogenesis, including the maintenance of leukemic
stem/progenitor cells in osteoblast-containing endosteal
niches and in endothelium-containing vascular niches in
the bone marrow [1, 2]. Studies of antileukemic drugs
mainly focus on the pharmacological effects on the AML
cell populations whereas pharmacological effects on the
AML-supporting stromal cells are not so well characterized,
especially not in studies of the low-toxicity disease-stabilizing
therapeutic alternatives [3–6]. Several clinical studies have
described an AML-stabilizing effect of valproic acid (VPA)
in combination with all-trans retinoic acid (ATRA) and
eventually cytotoxic drugs (e.g., Ara-C) [6–14]. VPA is a
short-chain fatty acid that has multiple anticancer actions
including HDAC inhibitory activity and can affect AML
cell proliferation [15, 16], whereby ATRA is a vitamin A
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derivative that mainly interferes with regulation of differ-
entiation and apoptosis in AML [17, 18]. Previous studies
have demonstrated that all three drugs have direct effects
on primary human AML cells [16, 17, 19]. Furthermore,
previous in vitro studies have characterized the cytokine-
mediated crosstalk between AML cells and neighbouring
stromal cells (i.e., osteoblasts and endothelial cells) [20,
21]. This bidirectional leukemia/stromal crosstalk increased
AML cell proliferation and could also affect the stromal
cells [21, 22]; pharmacological targeting of AML would
therefore be expected to indirectly affect the stromal cells,
but antileukemic chemotherapy may also have additional
direct effects on the stromal compartment that indirectly
affect the leukemic cells and thereby contribute to the
overall antileukemic activity. Such additional direct effects
on stromal cells were recently described for pharmacological
inhibition of the PI3K-Akt-mTOR pathway [23].
In the present study, we used in vitro experimentalmodels
to investigate how VPA, ATRA, and Ara-C directly affect
endothelial cells and osteoblasts. The present results show
that both VPA and Ara-C had antiproliferative effects on
both stromal cell types, while ATRA did not significantly
affect cell proliferation. Our functional assays of endothelial
migration and capillary-like tube formation showed that VPA
elicited an antiangiogenic effect in vitro whereas ATRA had
a slightly proangiogenic effect. In addition, ATRA and VPA
affected endothelial cell release of several factors that are
involved in regulation of angiogenesis and/or can mediate
a growth-enhancing effect on primary human AML cells.
Altogether, our current results suggest that pharmacological
effects of VPA/ATRA/cytarabine on stromal cells should be
further investigated during clinical treatment as inhibition of
stromal cell activity may potentially contribute to the overall
antileukemic activity via alteration of growth factors involved
in AML cell proliferation and bone marrow angiogenesis.
2. Materials and Methods
2.1. Pharmacological Agents and Culture Medium
2.1.1. Pharmacological Agents. VPA (Desitin Pharma AS,
Hamburg, Germany) was purchased as a dissolved salt
solution. ATRA (Roche, Oslo, Norway) powder was dissolved
in ethanol. Cytosine 𝛽-D-arabinofuranoside (Ara-C) was
purchased from Sigma-Aldrich and dissolved in sterile water.
Stock solutions of each drug were made and kept stored at
−80∘C. Control cultures for comparisons with VPA and Ara-
C treated cultures were added a solution of 0.9% NaCl, while
ethanol was added to control cultures for ATRA.
2.1.2. Culture Medium. We have previously investigated the
effects of endothelial cells and osteoblasts on AML cell pro-
liferation [20, 24], and the functional in vitro characteristics
of Cal72 osteoblastic sarcoma cells were also investigated in
detail in a previous study where the cells were cultured in
various media [25]. The culture media used in the present
study for Cal72 and endothelial cells are the same media
used in our previous coculture studies. HUVECs were there-
fore cultured in EGM-2 medium (Lonza), while Cal72 was
grown in Stem Span SFEM culture medium (referred to as
StemSpan; Stem Cell Technologies, Vancouver, BC, Canada)
supplemented with 10% heat inactivated fetal calf serum
(FCS) (BioWhittaker, Verviers, Belgium) and 100 𝜇g/mL of
gentamicin.
2.2. Cells and Culture Conditions. Human umbilical vein
endothelial cells (HUVECs) and pulmonary artery smooth
muscle cells (Pa-vSMC) were purchased from Lonza (cat no.
C2517A and CC-2581, Verviers, Belgium), and the human
osteosarcoma cell line Cal72 was purchased from Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ,
cat no. ACC439, Braunschweig, Germany). Cal72 is more
closely related to normal osteoblasts than other characterized
osteosarcoma cells [26]. Unless otherwise stated, cells were
maintained in a humidified atmosphere of 5% CO
2
at 37∘C.
Cultures reaching 70–80% confluence were subcultured with
a trypsin-EDTA solution (Lonza). Cell viability was evaluated
by counting Trypan blue dye-excluding cells.
2.3. Proliferation Assays
2.3.1. 3H-Thymidine Assay. Cells were cultured with or
without drugs in flat-bottomed 96-well plates (NucleonTM
Surface, Nunc A/S, Roskilde, Denmark). HUVECs were
seeded at 2 × 103 cells per well and Cal72 cells at 4 × 103
cells per well in a total volume of 150 𝜇L per well in their
respective medium. Drugs were added 18 h after seeding, and
cultures were incubated for 2 days before addition of 3H-
thymidine in 20𝜇L of 0.9% NaCl solution (37 kBq per well,
TRA 310, Amersham, UK). After 24 h, cells were transferred
to a UniFilter (−96, GF/C; PerkinElmer Inc., Wellesley, MA,
USA), Microscint scintillation fluid was added (PerkinElmer
Inc.), and nuclear radioactivity was assayed (TopCount NXT;
PackardBioScience/PerkinElmer,Wellesley,MA,USA).Only
cpm values above 1000 were considered as detectable pro-
liferation after 3H-thymidine incorporation. All experiments
were performed in triplicate. In certain experiments, cells
were cultured at low oxygen levels. Cell cultures were then
placed in a multigas incubator (MCO-175M, Sanyo, Electric
Co., Ltd, Tokyo, Japan) which was flushed with 5% CO
2
and 94% N
2
. Cells were treated with drugs and incubated
either at standard conditions (21% O
2
) or at 1% O
2
before the
proliferative rates were assessed.
2.3.2. Cell Counting. Endothelial cells were seeded at 1 × 104
cells/cm2 into 6-well plates (TPP, Trasadingen, Switzerland).
After drug treatment for 3 days, viable cells were discrimi-
nated from dead cells by microscopy using a 0.4% Trypan
Blue dye solution (Invitrogen).
2.4. Culture Supernatants and Cytokine Analysis. Cell-free
supernatants were collected fromHUVECs cultured in 6-well
plates (TPP, seeding density of 1 × 104 cells/cm2) incubated
with or without drugs for 3 or 5 days. Supernatants were
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stored frozen at −20∘C until analysis. The multiplex analysis
kit (Angiogenesis CustomPrefix kits, R&DSystems)was used
to measure the following ten analytes in supernatants, VEGF,
VEGF-D, PIGF, bFGF, PDGF-AA, PDGF-BB, angiopoietin-
1 (Ang-1), angiogenin, endostatin, and thrombospondin-
2. Concentrations of CXCL8, CXCL10, MMP-2, sVEGFR1,
sVEGFR2, and HGF in supernatants were determined in
duplicates using Quantikine enzyme-linked immunosorbent
assays (ELISA) (R&D Systems, Minneapolis, MN, USA).
2.5. Endothelial Migration Assay. HUVECs were seeded into
6-well plates and preincubated with VPA (0.3–2.4mM) or
ATRA (0.01𝜇M–1 𝜇M) for 3 days, then harvested and washed
before being resuspended in EBM-2 media (basal medium
without added growth factors or serum). A total of 5 × 104
viable cells in 0.2mL EBM-2 were seeded into 8𝜇m pore
inserts in 24-well plates (Falcon), and the lower chamber
was added 20% FBS in 0.5mL EBM-2 as a chemoattractant.
After 6 h of incubation, cells on the upper side of the porous
membrane were removed, while migrated cells on the lower
membrane surface were fixed with paraformaldehyde and
stained with 5 𝜇g/mL Hoechst 33342 for nuclei visualization.
For each membrane, four fields of view were imaged using
a 10x objective on a Zeiss AxioObserver microscope. ImageJ
software (NIH Image, NIH) was used to quantify the number
of migrated endothelial cells.
2.6. Endothelial Capillary-Like Network Formation Assay. We
used the in vitro coculture angiogenesis assay as described
in detail previously [27, 28]. Briefly, early passage HUVECs
were infected with retrovirus carrying a fluorescent (GFP)—
expressing construct. HUVECs and Pa-vSMCs were simul-
taneously seeded into half-area 96-well plates (cat. no.
675090; Greiner Bio-One, Essen, Germany); plates were then
centrifuged at 200 g and incubated for 4 h to allow cell
attachment before addition of drugs (50𝜇L per well, total
volume per well 150 𝜇L). Cells were seeded into complete
EGM-2 when testing for antiangiogenic activity, while EBM-
2 medium supplemented with only hydrocortisone, ascorbic
acid, gentamicin, heparin, and 2% FBS (all from the EGM-2
bullet kit) was used when testing for potential proangiogenic
activity of drugs [29]. Cocultures were automatically imaged
using the BD Pathway 855 high-throughput BioImager (BD
Biosciences, San Jose, CA). Images were acquired as 2 × 2
montages to enlarge the view field using a 10x objective,
with an excitation filter 488/10 and emission filter 520/35
to visualize GFP-expressing cells. Image-based autofocus
ensured to bring cells into focus in every well to obtain high
quality images.
2.7. Statistical Analyses. All data were analyzed using Graph-
Pad (GraphPad Prism 5 Software, CA, USA). Standard error
of the mean (SEM) is shown when at least three independent
experiments are performed, and one-way ANOVA with
Tukey’s multiple test was used for multiple comparisons
between treatments (expressed as percentage of control
values). The inhibitory concentration of 50% (IC
50
) was cal-
culated as the concentration of drug yielding 50% reduction
compared with untreated control.
3. Results
3.1. Effects of VPA, ATRA, and Cytarabine on Stromal Cell Pro-
liferation: A Comparison of HUVEC and Osteoblastic Cal72
Cells. Bone marrow angiogenesis seems to be important for
leukemogenesis and also chemosensitivity in human AML,
and both endothelial and osteoblastic cells are able to support
the proliferation of primary humanAML cells [20, 24]. In this
context, we investigated the effects of the AML-stabilizing
drugs VPA, ATRA, and cytarabine on growth of osteoblastic
Cal72 cells and HUVECs. The cells were cultured for 3 days
with different concentrations of VPA (0.15–9.6mM), ATRA
(0.001–20𝜇M), and Ara-C (0.01–20 𝜇M) before proliferation
was analyzed using the 3H-thymidine incorporation assay.
VPA and Ara-C had dose-dependent antiproliferative effects
for both endothelial and osteoblastic cells (Figures 1(a) and
1(b)). ATRA 20 𝜇M caused a significant decrease of HUVEC
proliferation, but ATRA did not significantly inhibit HUVEC
orCal72 proliferationwhen tested in the range from0.001𝜇M
to 2𝜇M. HUVEC cell growth was significantly inhibited by
VPA concentrations ≥0.15mM compared to drug-free con-
trol cultures, while Cal72 growth was significantly inhibited
by a higher dose (2.4mM) of VPA compared to control
cultures (Tukey’s multiple test, 𝑃 < 0.05, 𝑛 = 3). In addition,
0.01 𝜇M Ara-C significantly inhibited cell growth compared
to drug-free control cultures for both HUVEC and Cal72
(Tukey’s multiple test, 𝑃 < 0.05, 𝑛 = 3).
IC50 values for VPA in the 3H-thymidine proliferation
assay were 1.1mM for HUVEC and 4.8mM for Cal72. The
IC50 values obtained after Ara-C treatment were 19.1 nM for
HUVECs and 95.1 nM for Cal-72. The effect of cytarabine on
cell proliferation was in addition tested at two different con-
centrations (0.1 and 1 𝜇M) in combination with VPA (0.3 and
0.6mM) and/or ATRA (1 𝜇M). Serum levels corresponding
to these Ara-C concentrations can be reached during low-
dose Ara-C therapy [30]. A similar antiproliferative effect
of Ara-C was observed also in the presence of VPA as
well as ATRA for both cell types, and VPA/ATRA did not
alter the proliferation compared to treatment with cytarabine
alone at these concentrations (Figure 1(c), results shown for
HUVECs).
We also examined the effects of Ara-C combined with
VPA and ATRA on stromal cell proliferation at low oxygen
levels, and the proliferation of both HUVEC and Cal72
was reduced with >50% when cells were cultured in drug-
free conditions at 0.1% O
2
compared with culture at 21%
O
2
. Even though growth was reduced during low oxygen
levels, cpm values above 5000 were measured in drug-free
cultures after 0.1% O
2
culture, and a similar growth-reducing
effect was seen for Ara-C (0.1 and 1 𝜇M) and VPA (0.3
and 0.6mM) when both stromal types were incubated at
0.1% O
2
compared to 21% O
2
, relative to their respective
control cultures grown at the same oxygen concentrations,
and VPA/ATRA did not alter the proliferation compared to
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Figure 1: Effects of VPA, ATRA, and Ara-C on stromal cell proliferation. (a) HUVECs and (b) Cal72 cells were incubated with various
concentrations of VPA, ATRA, or Ara-C for 3 days and proliferation was measured as incorporation of 3H-thymidine the last 24 hours of
incubation. (c) The figure shows the effect of Ara-C (0.1𝜇M), VPA (0.3 and 0.6mM), and ATRA (1 𝜇M) treatment on HUVEC proliferation
alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three
independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
treatmentwithAra-C alone (data not shown).Thus, the dose-
dependent antiproliferative effects of Ara-C on both HUVEC
and Cal72 cells was maintained in the presence of VPA and
ATRA also during culture at low oxygen levels.
3.2. Viable Cell Counts after Treatment of HUVECs with
VPA and ATRA. HUVECs were cultured for 3 days in the
presence of VPA or ATRA before the number of viable cells
was determined by counting Trypan blue dye-excluding cells.
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Figure 2: Effects of VPA and ATRA on endothelial cell viability. HUVECs were treated with VPA and ATRA for 3 days and viable cells were
counted as Trypan blue dye-excluding cells. The number of cells decreased after VPA treatment in a dose-dependent manner, while ATRA
did not alter the number of viable cells, and the percentage of viable cells was >80% after treatment with all doses of ATRA. Results are shown
as the mean number of viable cells in percent compared to control cultures ± SEM, for three independent experiments (∗𝑃 < 0.05, Tukey’s
multiple test).
VPA (range 0.3–2.4 nM) caused a dose-dependent reduction
in the number of viable cells (𝑃 < 0.05, control versus 2.4mM
VPA), while ATRA (range 0.01–1 𝜇M) did not significantly
alter the number of viable cells and the amount of viable
cells was >80% compared to control cultures after treatment
with all doses of ATRA (Figure 2). The percentage of dead
cells (Trypan Blue stained) was less than 10% after treatment
of all doses of VPA and ATRA. These results correspond to
the cell proliferation results, where ATRA did not affect cell
growth at concentrations below 2 𝜇M, though VPA inhibited
cell proliferation with increasing concentrations.
3.3. Effects of VPA and ATRA on Migration and Capillary-
Like Network Formation by HUVECs. AML is characterized
by increased bonemarrow angiogenesis [31], and this process
depends on endothelial cell proliferation as well as endothe-
lial cell migration and organization. To examine whether
VPA and ATRA have effects on endothelial cell migration,
cells were incubated with VPA (0.3/0.6/1.2/2.4mM) or ATRA
(0.01/0.1/1 𝜇M) for 3 days and cell migration was determined
using transwell culture inserts. A dose-dependent decrease
of HUVEC migration was observed after 3 days of VPA
treatment (Figures 3(a) and 3(b)), while cell migration was
enhanced by increasing doses of ATRA compared to the
respective controls.
A coculture assay was used to investigate the effects of
VPA and ATRA on endothelial cell capillary-like formation
in vitro. HUVECs in coculture with Pa-vSMCs generate
capillary-like networks in the presence of growth-factor
rich endothelial culture medium (EGM-2), but neither VPA
nor ATRA altered the degree of network formation when
added to cocultures in this growth-factor rich medium;
however, VPA showed potent inhibition of capillary-like
network formation in a dose-dependent manner when added
to cocultures grown in the growth factor-reduced EBM-2
medium (Figure 4(b)), whereas enhanced network formation
was seen after treatment with ATRA (Figure 4(a)). Hence, we
used two different assays to investigate endothelial cell migra-
tion/organization that are important steps in the process of
angiogenesis; VPA then caused an inhibition of HUVEC
migration/capillary-like tube formation in both assays while
ATRA seemed to have an enhancing effect in these assays.
3.4. Effects of VPA and ATRA on the Release of Soluble
Mediators by Endothelial Cells. Previous experimental stud-
ies have demonstrated that the cytokine-mediated crosstalk
between primary humanAML cells and endothelial cells pro-
motes leukemia cell proliferation [20, 21, 24]. This crosstalk-
dependent growth enhancement can be mediated by various
cytokines including IL1, GM-CSF, VEGF, CXCL8, and HGF,
but the relative contribution of each mediator seems to vary
between patients [21]. Investigation of the cytokine release
profile of HUVECs showed that these cells release very low or
undetectable levels of IL1𝛽, GM-CSF, and HGF under in vitro
culture conditions; however, they release (i) several media-
tors important for angioregulation including MMP-2, endo-
statin, and various angioregulatory chemokines [32]; and (ii)
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Figure 3: Effects of VPA and ATRA on endothelial cell migration. (a) HUVECs were treated for 3 days with VPA-concentrations ranging
from 0.3mM to 2.4mM and ATRA-concentrations from 0.01 𝜇M to 1 𝜇M before cell migration through 8 𝜇m pore filters was determined
using a transwell assay. Results are shown as mean migrated cells ± SEM (percent migrated cells compared to control cultures) for three
independent experiments (∗𝑃 < 0.05, Tukey’s multiple test). (b) Images show Hoechst-stained migrated cells on transwell filters for the
highest drug concentrations of VPA and ATRA resulting in significantly altered cell migration. A representative drug-free control image for
comparison with treated cultures is shown.
cytokines known to promote AML cell proliferation includ-
ing CXCL8 and PDGF [32, 33]. Drug-induced modulation
of angioregulatory cytokine production and consequently
altered communication between neighboring cells could be a
possible explanation for the altered tube formation described
above, and in this context we investigated the effects of VPA
and ATRA on angioregulatory mediators and AML growth-
enhancing factors released during culture of HUVECs. The
culture medium EGM-2 was supplemented with growth
factors provided by the distributor and we then measured
high levels of bFGF (720 pg/mL) and VEGF (554 pg/mL) in
culture medium alone, whereas low/undetectable levels of
VEGF (<20 pg/mL) and bFGF (<100 pg/mL) were detected
in the supernatants after culture of HUVECs for 3–5 days.
High Ang-1 levels (652 pg/mL) were also found in the culture
media, though levels were not altered during culture.
In supernatants collected from HUVECs cultured
alone for 5 days, we measured detectable release of
angiogenin (2157 pg/mL), PDGF-AA (1292 pg/mL), PDGF-
BB (1500 pg/mL), endostatin (5523 pg/mL), thrombospondin
(169 pg/mL), PIGF (149 pg/mL) and VEGF-D (143 pg/mL),
CXCL8 (368 pg/mL), MMP-2 (116 ng/mL), sVEGFR-1
(>200,000 pg/mL), and sVEGFR-2 (152 pg/mL), while
HUVEC did not produce HGF or CXCL10, and detectable
release of these latter two cytokines were not induced
by addition of VPA or ATRA. However, VPA and ATRA
modified the release of several mediators in a dose-
dependent manner compared to levels found in untreated
controls (Figures 5(a) and 5(b)). These dose-dependent
effects were most clearly seen after 5 days compared to
treatment for only 3 days, and therefore only levels measured
after 5 days of treatment are shown in Figure 5. Both VPA
and ATRA caused a dose-dependent decrease of MMP-2
levels. Proangiogenic CXCL8 levels increased in the presence
of ATRA while no dose-dependent effect on CXCL8 levels
was seen after VPA treatment. CXCL8 levels were altered the
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Figure 4: Altered endothelial cell network formation after treatment with VPA and ATRA. Representative images acquired after 3 days
of coculture in the presence of drugs show network formation after (a) treatment with ATRA and (b) treatment with VPA. A representative
image of a drug-free control culture is shown for comparison with VPA and ATRA treated cultures. Pa-vSMCs form a confluent layer beneath
the HUVECs, but only the fluorescent endothelial cells are visible in the images.
most of all the mediators examined; levels increased from
254 pg/mL in drug-free control cultures to 13,887 pg/mL
(a 54-fold increase) after 1𝜇M ATRA treatment for 5 days.
Thrombospondin-2, endostatin, angiogenin, and PIGF levels
were slightly reduced by VPA treatment, while unaltered
levels of thrombospondin-2 and angiogenin were seen after
ATRA treatment, and in addition, PDGF-BB levels were
slightly increased by ATRA treatment (data not shown).
HUVEC controls treated with ethanol and 0.9% NaCl had
no effects on the release of mediators.
We measured levels of sVEGFR1 and sVEGFR2 released
by HUVEC cells, which are truncated isoforms of VEGFR1
and VEGFR2, respectively. VPA decreased levels of sVEGFR1
and sVEGFR2, while slightly increased levels were found
after ATRA treatment (data not shown). In summary, medi-
ator levels were generally decreased after VPA treatment,
while divergent results were seen after ATRA treatment. As
VPA had antiproliferative effects, we compared the ratio
of proliferation/mediator release measured after treatment
with 0.6mM VPA to see if effects of VPA-treatment on cell
proliferation may account for the reduced levels of mediators
released by HUVECs. The ratio varied between the differ-
ent mediators indicating that other effects besides reduced
proliferation/cell numbers also contribute to modulation of
endothelial mediator release (Figure 6). Taken together, these
observations show that ATRA andVPA can affect endothelial
cell release of several mediators that are (i) known to be
involved in regulation of angiogenesis [32] and/or (ii) have
a growth-enhancing effect on primary human AML cells
during in vitro coculture of leukemic cells with endothelial
cells [24].
4. Discussion
Stromal cells are involved in regulation of both normal
and leukemic hematopoiesis [1, 2, 34, 35], and AML
chemotherapy seems to have indirect antileukemia effects
mediated via effects on stromal cells. Furthermore, low-
toxicity disease-stabilizing treatment based on VPA, ATRA,
and eventually conventional cytotoxic drugs is being consid-
ered in the treatment of humanAML. In this context, we used
HUVECs as a model system for in vitro studies of endothelial
cell function after treatment with VPA, ATRA, and low con-
centrations of Ara-C on endothelial cells and also performed
comparative growth studies using the Cal72 osteosarcoma
cell line that has been used in several experimental studies
and is regarded to have an osteoblastic phenotype [26]. Alto-
gether, our study suggests that pharmacological agents used
in disease-stabilizing treatment of humanAMLdirectly affect
stromal cells and thereby may have indirect antileukemic
activity. A possible antileukemic mechanism is then reduced
release of cytokines by stromal cells that are known tomediate
growth enhancement of the leukemia cells during in vitro
coculture of primary human AML cells and endothelial cells
[24].
We have previously used in vitro cocultures of leukemic
and stromal cells to demonstrate that endothelial as well
as osteoblastic cells can have a cytokine-mediated growth-
enhancing effect on primary humanAMLcells [20, 24]. In the
present study, we used the same culture conditions as used in
our previous coculture studies, and we then show that VPA
and Ara-C inhibit endothelial cell proliferation (also seen for
osteoblastic cells), while VPA andATRA alter endothelial cell
migration and cytokine release. The experimental conditions
were similar in both our previous coculture and current
culture studies, and we now observed altered release of solu-
ble mediators including both angioregulatory mediators and
cytokines that can function as AML growth factors during
coculture of AML and stromal cells.The drug-induced effects
on HUVEC proliferation and migration/orientation may
then represent a second indirect antileukemic mechanism
that interferes with leukemia-induced angiogenesis.
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Figure 5: VPA and ATRA modify the release of diffusible mediators from endothelial cells. Concentrations of soluble mediators were
determined in HUVEC culture supernatants after treatment with different doses of VPA or ATRA for 5 days. Colorimetric ELISA kits and a
Luminex assay using multianalyte profiling beads were utilised to determine the different mediator concentrations in duplicate samples after
treatmentwith (a)VPA and (b)ATRA.The results are presented as themean percent alteration (duplicate samples) ofmediator concentrations
found in treated cultures compared with their respective drug-free control cultures containing 0.9% NaCl (VPA control) or ethanol (ATRA
control).
Several clinical studies have investigated VPA in combi-
nation with other drugs for the treatment of AML [7–10, 14,
36, 37], and the concentrations of VPA and ATRA utilized in
our in vitro assays are based on serum levels reported in these
clinical studies [38]. The median serum level of VPA in one
study was 360𝜇M (range of 214–743 𝜇M) [38], but response
to treatment can be seen even at lower concentrations [3].
Therefore, we chose to use a low dose of VPA 300 𝜇M, an
intermediate dose of 600𝜇M, and high doses of ≥1200𝜇M
in our assays. ATRA plasma levels have a high interpatient
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Figure 6: The relative ratio of cell proliferation versus mediator
release from HUVECs after VPA treatment. The proliferation of
HUVECs after 0.6mM VPA treatment was reduced to 71% of
drug-free controls, and the figure shows the relative ratio values of
proliferation after 0.6mM VPA treatment versus the concentration
of various soluble mediators measured in HUVEC cultures after
0.6mM VPA treatment.
variability, and patients treated with ATRA were shown to
have significantly decreased plasma levels after a few days of
treatment and levels remained low or undetectable even after
treatment with increased doses [39]. Following the usual oral
dose of 45mg/m2ATRA,median peak plasma concentrations
were measured to be 1 𝜇M [40]. In addition, one of the first
studies of ATRA showed an effect on leukemia cell lines in
vitro at 0.001𝜇M, with a maximum effect on differentiation
at 1 𝜇M [41], and therefore the physiological relevant level of
1 𝜇MATRA was chosen for all our experiments.
Cytarabine is a deoxycytidine analogue [19] that is
metabolized to its active triphosphate form that inhibits
deoxyribonucleic acid polymerase-𝛼 and is incorporated into
elongating DNA strands and thereby causes chain termina-
tion. The serum levels of Ara-C depend on the dose and
administration of the drug: (i) conventional doses vary from
100 to 200mg/m2 given by intermittent injection of continu-
ous infusion over 5–10 days and result in steady-state plasma
levels of 0.1–1 𝜇M[42]; (ii) high-dose protocols administering
the drug as 1–3 g/m2 results in peak concentrations of 100 𝜇M
(up to 300 𝜇M in children) but a rapid fall to 0.11–8.25𝜇M
[19, 43, 44]; and (iii) low-dose therapy with 10–20mg/m2
once or twice daily reaches maximal levels of 0.2–0.6𝜇M 15
minutes after the injection when using 10mg/m2 [30] and
this is well above 0.1 pM that is assumed to be required for
cytotoxicity [19]. Furthermore, the active metabolite uracil
arabinosidemay show 5–8-fold higher serum levels thanAra-
C and has a relatively long half-life [43]. We tested Ara-
C at a concentration range from 0.01 to 20 𝜇M; the lower
concentrations of 0.01–5𝜇M are then considered relevant for
low-dose cytarabine therapy and these concentrations will
then result in cytotoxic activity. Our results demonstrate
that the cytotoxic/antiproliferative effects of these low Ara-
C levels are maintained in the presence of clinically relevant
VPA and ATRA levels. Other studies have reported other
IC50 values after VPA or Ara-C treatment of HUVECs
than those we found in our in vitro proliferation assay [45,
46]; however, IC50 values may vary due to the utilization
of different assays, different incubation time of drugs, and
the end point concentration values used [47]. However, the
observations by Michaelis et al. [45] support the clinical
observations that VPA can have antileukemic effects in vivo at
concentrations lower than the generally accepted therapeutic
serum level used for antiepileptic therapy.
Our present study investigated the in vitro effects of VPA
and ATRA on various steps in the process of angiogenesis.
Previous studies have investigated how ATRA modulates
angiogenesis, though the results are not clarifying as both a
stimulating and inhibitory effect on angiogenesis has been
shown [48–50]. We therefore investigated the effect of ATRA
on endothelial cells using two different assays to examine
angiogenesis. ATRA enhanced the migration of HUVECs as
well as the organization of endothelial cells into capillary-
like networks in a dose-dependent manner, which supports
a proangiogenic effect of ATRA. In contrast, VPA inhibited
the ability of HUVECs to migrate and decreased capillary-
like networks in our coculture model of endothelial cells and
supporting vascular smooth muscle cells that form capillary-
like vessels and thereby mimics in vivo conditions [27]. Our
present observations of an antiangiogenic effect of VPA in
vitro are in concordance with studies of VPA and other
HDAC inhibitors in other experimental models [45, 51].
In our functional in vitro assays, ATRA enhanced
HUVEC migration and network formation and increased
the levels of several proangiogenic factors, including CXCL8
and VEGF-D. One possible mechanism for increased expres-
sion may be due to ATRA-induced upregulation of HIF-
1𝛼 expression [52]. However, ATRA also reduced levels of
proangiogenic MMP-2, which concords with findings by
another study [53]. These observations reflect that there is a
complex balance between the collective action of proangio-
genic and antiangiogenic factors which influences the final
effect on the process of angiogenesis [29], and in addition,
other effects (e.g., antiproliferative and proapoptotic) may
not be reflected in our in vitro models of angiogenesis.
ATRA strongly enhanced the release of angiogenic mediators
including CXCL8 by the endothelial cells; this may in vivo
either result in (i) direct effects on autocrine cell signaling, (ii)
inhibition of effects that ECs have on pericytes surrounding
blood vessels or other stromal cells in the bone marrow,
or (iii) it may potentially have an indirect paracrine effect
on leukemia cells in vivo. We did not see an effect of VPA
on CXCL8 release, though similar therapeutically relevant
VPA-concentrations have been shown to induce the mRNA
expression of other members of the CXC chemokine family
in HUVECs [54]. Diffusible factors secreted from endothelial
cells have also been shown to have a role in maintenance of
hematopoietic stem cells (HSCs) and leukemia cells [34, 35].
Even though our in vitro results should be interpreted
carefully, our observations suggest that VPA may mediate
antileukemic activity in part through inhibition of angiogen-
esis; this is supported by the observed antiproliferative effects
on HUVEC cells, the inhibition of proangiogenic factors
10 Leukemia Research and Treatment
released by HUVECs and reduced HUVEC migration and
capillary tube formation. Other studies have also shown that
VPA induces G0/G1 cell cycle arrest of both HUVECs and
AML cells [55, 56], which is consistent with our findings
of a reduced cell number after VPA treatment and a low
amount of dead cells (Trypan-blue excluding cells). Con-
tinuous VPA treatment can be combined with intermittent
ATRA therapy for disease-stabilizing treatment in human
AML [6, 10, 17], and it is more likely that the antiangiogenic
and antiproliferative effects of VPAwould then be regarded as
more important than the proangiogenic effects mediated by
ATRA, though further studies must be performed to address
the relative importance of direct versus indirect antileukemic
effects during AML-stabilizing treatment.
Altogether, our results suggest that VPA acts not only as a
direct antileukemic drug, but may also exert antiproliferative
and antiangiogenic activity on the stromal cell compartment
that in turn may have indirect antileukemic effects. However,
it is recognized that these in vitro studies are limited in
that they are conducted apart from the leukemic microen-
vironment. Our present studies were performed by using
the same experimental conditions as for previous coculture
experiments [20, 24], and the described pharmacological
effects include reduced endothelial cell release of AML
growth factors thatmediate the endothelium-induced growth
enhancement during coculture. The effects on endothelial
cell proliferation/migration/orientation may represent a sec-
ond indirect antileukemic effect by these drugs through
altered local angioregulation. VPA and ATRA may also be
combined with other antileukemic drugs, for example, 5-
mercaptopurine, hydroxyurea, and 5-azacitidine [9, 12, 57],
and only future clinical studies can clarify which combi-
nation is optimal. However, ATRA/VPA/cytarabine-based
treatment is effective only for a subset of patients [16, 38], and
future clinical studies should also investigate whether new
biomarkers can be used to identify patients that will respond
to treatment.
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